Reading WST? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track WST free→
West Pharmaceutical Services (WST)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Intact
$329.55-0.57%
Close 2026-06-16 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is neutral, and the sector backdrop is a headwind, indicating challenges in the current environment. Peer multiples imply a price about 93% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. Key factors to watch include any guidance cuts from WST and the performance of sector bellwethers like ISRG, MDLN, and BDX. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Medical Instruments & Supplies
- Market cap
- $23.41B
- Employees
- —
- IPO date
- 1994-05-13
- Next earnings
- 2026-07-23
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 8 valuation methods, at three horizons. Current price $329.55. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$170.75consensus
Range $165.03 – $201.24
vs price: +93% above
Method agreement — · 8 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearexpensive
$235.01consensus
Range $210.15 – $335.57
vs price: +40% above
Method agreement — · 6 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearfull
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Durable premiumlow confidence
At $330 the market pays 42× p/e — above the 20× p/e peer median but in line with its own 40× history. That premium reflects a durable franchise our peer-anchored $171 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts: $310–$400. Not investment advice.
Multiple (P/E)
41.6x
peer 19.8x · own history 40.5x
Premium
2.1x peer
1.0x its own history
Growth the price needs
93%
our forecast 10%
Our fair value
$170.75
range $165.03 – $201.24
Analyst range(a guide on our number, not a target)Our number is below the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced inUnjustified
The market is pricing in roughly 93% near-term growth, well above our forecast of about 10%. This describes what's priced in, not a forecast of the move.
Elevated fragilityrisk posture, not a price call
Flags: expensive valuation, weak execution quality. Capped at elevated by the Mania regime.
Historical context
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
93rd pctl · Health Care
Earnings quality
neutralOver the trailing year it converted 1.32x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
44th pctl · Health Care
Macro sensitivity
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
Management & capital allocation
volatile17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Bullish11 analysts, 82% Buyfor period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $2.08 → $2.08 (-0.2% / 30d). 0 raised, 1 cut, 11 covering analysts.
Rating actions
1 upgrade, 0 downgrades / 30d, 2 maintained. 82% of analysts rate Buy.
Price target activity
1 PT revisions / 30d. Avg target 25.1% above current price.
Material events
0 positive, 0 negative / 30d.
Transition story with positive analyst positioning (often a turnaround setup).
Sector context
Intermediate · WeeklyManagement scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: strong
- Capital allocation
- strong
- Earnings discipline
- strong
- Margin discipline
- strong
- Balance sheet
- strong
- Post-call reaction
- weak
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$112.
How much price usually moves either way.
On a bad day, this stock has moved -$319.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,470.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideHigh confidenceWeeksactive 22d
Watch for Q2 2026 net sales guidance announcement
Why it matters: Guidance for Q2 sales can show if demand and operations are strong.
What confirms / what disproves
Confirms:Management announces Q2 net sales guidance in the range of $830 million to $850 million.
Disproves:Management lowers Q2 net sales guidance or provides no guidance at all.
Management priorities
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-06-161d agoYahoo! Finance
Advances: Increase full-year 2026 revenue guidance
Upgrade indicates strong growth potential for 2026 revenue.
Strongly reinforcesUnconfirmed report
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ISRG, MDLN, and BDX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting WST and other Healthcare names. Worth watching these names for early signals.
- If WST raises forward guidance on the next earnings call (currently NEW as of 2026-04-23), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
- If WST beats again next quarter like it did this past one (a big beat of +27% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
Downside triggers
- If WST cuts guidance on the next call (currently NEW as of 2026-04-23), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like ISRG, MDLN, and BDX start missing or guiding lower, the Healthcare tailwind helping WST and other Healthcare names could fade. Watch these names for early warning.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-0116d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 9, 2026, West Pharmaceutical Services, Inc. (the “Company”) filed a Current Report on Form 8-K announcing that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been h…
Executive changeneutral
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-1.9 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.